[Market Focus] Alphabio's ACV Production Surges Tenfold in a Year... Emerging as a "Game Changer" in the Health Supplement Market

Alphabio is showing strong performance. This appears to be influenced by news that the production volume of products related to Apple Cider Vinegar (ACV) has surged more than tenfold in just one year.

As of 11:14 a.m. on September 23, Alphabio shares were trading at 7,250 won, up 3.57% from the previous day.

On this day, Alphabio announced that the production volume of ACV-related products exceeded 1.5 million packets in the first half of the year alone, representing a more than tenfold increase in just one year. Building on this growth, Alphabio plans to accelerate its market share expansion by targeting a cumulative production volume of 3 million packets by the end of the second half of this year.

This growth is attributed to the explosive demand in the health functional food market, combined with Alphabio's unrivaled formulation technology and global standard manufacturing processes. In particular, new supplement formats such as jellies, capsules, and tablets, which maximize convenience of consumption, are driving market growth, and Alphabio is being recognized for leading the market with its proprietary technology.

The core driver behind Alphabio's explosive growth is its "highly concentrated ACV blending and stabilization technology," which is based on 40 years of pharmaceutical manufacturing expertise. This technology completely eliminates the chronic drawbacks of conventional ACV products, such as strong sourness and pungent aroma, while stably preserving the active ingredients.

In addition, this technology enables the optimal blending of key ACV active ingredients with various functional materials (such as collagen, probiotics, and vitamins) without destroying their efficacy, providing the foundation for mass production of products that consumers can easily and comfortably consume without aversion.